StemCells, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments
SummaryMarketline's StemCells, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by StemCells, Inc. since January2007.
Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.
Key Highlights
This report includes StemCells, Inc.'s contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed.
The profile also includes detailed deal reports for all M&A, private equity, public offering, venture financing, partnership and divestment transactions undertaken by StemCells, Inc.. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed.
Scope
- Provides intelligence on StemCells, Inc.'s M&A, strategic partnerships and alliances, capital raising and private equity transactions.
- Detailed reports of various financial transactions undertaken by StemCells, Inc. and its subsidiaries since 2007.
- Information about key financial and legal advisors for StemCells, Inc.'s financial deals transactions.
- Financial deals tables and charts covering deal value and volumes trend, deal types and geography-based deal activity.
Reasons To Buy
- Access comprehensive financial deals data along with charts and graph covering M&A, private equity, and partnerships and alliances.
- Form an independent opinion about StemCells, Inc.’s growth strategies through the organic and inorganic activities undertaken since 2007.
- Track your competitors’ business structure and growth strategies.
Athersys is a biotechnology company that is focused in the field of regenerative medicine. The company's MultiStem? cell therapy, a patented and proprietary allogeneic stem cell product, is its primary platform product and is in clinical development. The company's existing clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the existing standard of care is limited or inadequate for a number of patients. The company has a collaboration with HEALIOS K.K., to develop and commercialize MultiStem for the treatment of certain indications in Japan.
BioCryst Pharmaceuticals is a biotechnology company that discovers oral, small-molecule medicines. The company focuses on oral treatments for rare diseases in which unmet medical needs exist and an enzyme plays the main role in the biological pathway of the disease. The company's drug/drug candidates include: Berotralstat (BCX7353), an oral serine protease inhibitor targeting kallikrein that is being developed as a once-daily oral therapy for the prevention of Hereditary Angioedema; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; and BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive.
CEL-SCI is a clinical-stage biotechnology company. The company is focused on the development of the following product candidates and technologies: Multikine, an investigational immunotherapy under development for the treatment of certain head and neck cancers; and Ligand Epitope Antigen Presentation System (LEAPS) technology, with two investigational therapies, CEL-2000 and CEL-4000, vaccine product candidates under development for the treatment of rheumatoid arthritis, and LEAPS-H1N1-DC, a product candidate under development for the potential treatment of pandemic influenza in hospitalized patients.
Geron is a biopharmaceutical company that is focused on the development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The company has global rights to imetelstat, a telomerase inhibitor, which was discovered and developed at the company Imetelstat has been granted both Orphan Drug and Fast Track designations by the United States Food and Drug Administration, for the treatment of patients with Low or Intermediate-1 risk myelodysplastic syndromes (MDS), or lower risk MDS, and for the treatment of patients with Intermediate-2 or High-risk MF relapsed after or refractory to janus kinase inhibitor treatment, or relapsed/refractory myelofibrosis.
Lineage Cell Therapeutics is a clinical-stage biotechnology company. The company's cell therapy programs in clinical development include: OpRegen?, a retinal pigment epithelium cell replacement therapy in a Phase 1/2a multicenter clinical trial for the treatment of dry age-related macular degeneration with geographic atrophy; OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries; and VAC2, a cancer immunotherapy of antigen-presenting dendritic cells in a Phase 1 clinical trial in non-small cell lung cancer.
MediciNova is a biopharmaceutical company focused on developing small molecule therapeutics for the treatment of diseases. The company is focusing its development activities on MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. The company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.
Seneca Biopharma is a clinical stage biopharmaceutical company that is utilizing its proprietary human neural stem cell technology to create a platform of therapies for the treatment of central nervous system diseases. The company's technology platform has produced four key assets, two in clinical development and two in preclinical development: its NSI-566 stem cell therapy program (clinical stage) for treatment of paralysis, NSI-189 small molecule program (clinical stage) for Major Depressive Disorder and NSI-532 for Alzheimer's Disease and NSI-577 indicated for potential use in treatment of human demyelinating diseases.
MarketLine, a world-leading provider of commercial intelligence, has over 400 experienced analysts, consultants, and researchers with regional and sector expertise in market sizing, competitor tracking, socio and macro economics, and business drivers.
For more than 15 years MarketLine has supported the research needs of investment banks, corporations, professional services firms, and academia with a unique mix of company, industry, country, city and financial data for every major industry and marketplace.
MarketLine’ holistic business intelligence report collection includes:
Industry Intelligence
‒ Industry Profiles
‒ Market Forecasts
‒ Porter’s Five Forces Analysis
Company Intelligence
‒ Company Profiles
‒ SWOT Analysis
‒ Financial Deals
Country and City Intelligence
‒ Country and City Profiles
‒ PEST/PESTLE Analysis
‒ Socio and macro-economic indicators
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.